Toll-like receptors in atherosclerosis: A 'Pandora's box' of advances and controversies

Trends in Pharmacological Sciences

Volumn 34, Issue 11, 2013, Pages 629-636

  Cole, Jennifer E ^a   Kassiteridi, Christina ^a   Monaco, Claudia ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

atheroma; inflammation; innate immunity; therapeutic

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; OPN 301; OPN 305; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CELL SPECIFICITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; REPERFUSION INJURY; REVIEW; SMOOTH MUSCLE FIBER;

ATHEROMA; INFLAMMATION; INNATE IMMUNITY; THERAPEUTIC;

ANIMALS; ATHEROSCLEROSIS; HUMANS; IMMUNITY, INNATE; TOLL-LIKE RECEPTORS;

EID: 84887406353     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.09.008     Document Type: Review

References (69)

1. A.D. Lopez Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data Lancet 367 2006 1747 1757
2. P. Libby Progress and challenges in translating the biology of atherosclerosis Nature 473 2011 317 325
3. C. Baigent Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
4. T. Mazzone Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data Circulation 122 2010 2201 2211
5. A.M. Gotto Jr, and J.E. Moon Recent clinical studies of the effects of lipid-modifying therapies Am. J. Cardiol. 110 2012 15A 26A
6. A. Hermansson Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis J. Exp. Med. 207 2010 1081 1093
7. J. Nilsson Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential Curr. Opin. Lipidol. 23 2012 422 428
8. A. Faggiotto, and R. Ross Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque Arteriosclerosis 4 1984 341 356
9. A. Faggiotto Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation Arteriosclerosis 4 1984 323 340
10. B. Lemaitre The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults Cell 86 1996 973 983
11. A. Poltorak Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene Science 282 1998 2085 2088
12. L.A. O'Neill The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress Immunol. Rev. 226 2008 10 18
13. I. Rifkin Toll-like receptors, endogenous ligands, and systemic autoimmune disease Immunol. Rev. 204 2005 27 42
14. J.E. Cole The expression and functions of toll-like receptors in atherosclerosis Mediators Inflamm. 2010 2010 393946
15. Y. Kondo TLR4-MD-2 complex is negatively regulated by an endogenous ligand, globotetraosylceramide Proc. Natl. Acad. Sci. U.S.A. 110 2013 4714 4719
16. S. Panigrahi Engagement of platelet toll-like receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis Circ. Res. 112 2013 103 112
17. H. Kumar Toll-like receptors and innate immunity Biochem. Biophys. Res. Commun. 388 2009 621 625
18. J.C. Kagan TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β Nat. Immunol. 9 2008 361 368
19. H. Bjorkbacka Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways Nat. Med. 10 2004 416 421
20. K.S. Michelsen Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E Proc. Natl. Acad. Sci. U.S.A. 101 2004 10679 10684
21. X. Liu Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids Atherosclerosis 196 2008 146 154
22. M. Madan, and S. Amar Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings PLoS ONE 3 2008 e3204
23. A. Mullick Modulation of atherosclerosis in mice by Toll-like receptor 2 J. Clin. Invest. 115 2005 3149 3156
24. A. Saxena The vascular repair process after injury of the carotid artery is regulated by IL-1RI and MyD88 signalling Cardiovasc. Res. 91 2011 350 357
25. A.H. Schoneveld Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development Cardiovasc. Res. 66 2005 162 169
26. A. Vink In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions Circulation 106 2002 1985 1990
27. K. Edfeldt Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation Circulation 105 2002 1158 1161
28. S. Frantz Mechanisms of disease: Toll-like receptors in cardiovascular disease Nat. Clin. Pract. Cardiovasc. Med. 4 2007 444 454
29. C. Monaco Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis Proc. Natl. Acad. Sci. U.S.A. 101 2004 5634 5639
30. C. Monaco Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis Circulation 120 2009 2462 2469
31. L.K. Curtiss Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists J. Lipid Res. 53 2012 2126 2132
32. T. Speer Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2 Immunity 38 2013 754 768
33. M.R. Richards The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice Innate Immun. 19 2013 20 29
34. A.M. Lundberg Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis Cardiovasc. Res. 99 2013 364 373
35. O. Pryshchep Vessel-specific Toll-like receptor profiles in human medium and large arteries Circulation 118 2008 1276 1284
36. X.H. Xu Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL Circulation 104 2001 3103 3108
37. A.E. Mullick Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events J. Exp. Med. 205 2008 373 383
38. G. Liuzzo Enhanced response of blood monocytes to in vitro lipopolysaccharide challenge in patients with recurrent unstable angina Circulation 103 2001 2236 2241
39. H. Methe Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome Circulation 111 2005 2654 2661
40. D. Versteeg Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve Heart 94 2008 770 776
41. M. Kashiwagi Differential expression of Toll-like receptor 4 and human monocyte subsets in acute myocardial infarction Atherosclerosis 221 2012 249 253
42. W. Shi Determinants of atherosclerosis susceptibility in the C3H and C57BL/6 mouse model: evidence for involvement of endothelial cells but not blood cells or cholesterol metabolism Circ. Res. 86 2000 1078 1084
43. M. Subramanian Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs J. Clin. Invest. 123 2013 179 188
44. A. Polykratis Conditional targeting of tumor necrosis factor receptor-associated factor 6 reveals opposing functions of Toll-like receptor signaling in endothelial and myeloid cells in a mouse model of atherosclerosis Circulation 126 2012 1739 1751
45. A. Niessner Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-α Circulation 114 2006 2482 2489
46. U. Ahmad IFN-γ primes intact human coronary arteries and cultured coronary smooth muscle cells to double-stranded RNA- and self-RNA-induced inflammatory responses by upregulating TLR3 and melanoma differentiation- associated gene 5 J. Immunol. 185 2010 1283 1294
47. J.E. Cole Unexpected protective role for Toll-like receptor 3 in the arterial wall Proc. Natl. Acad. Sci. U.S.A. 108 2011 2372 2377
48. M. Bsibsi The microtubule regulator stathmin is an endogenous protein agonist for TLR3 J. Immunol. 184 2010 6929 6937
49. K. Kariko mRNA is an endogenous ligand for Toll-like receptor 3 J. Biol. Chem. 279 2004 12542 12550
50. S. Zimmer Activation of endothelial toll-like receptor 3 impairs endothelial function Circ. Res. 108 2011 1358 1366
51. P. Chatterjee Placental Toll-like receptor 3 and Toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice PLoS ONE 7 2012 e41884
52. S. Goulopoulou Toll-like receptor 9 activation: a novel mechanism linking placenta-derived mitochondrial DNA and vascular dysfunction in pre-eclampsia Clin. Sci. (Lond.) 123 2012 429 435
53. J.H. Tinsley Toll-like receptor 3 activation during pregnancy elicits preeclampsia-like symptoms in rats Am. J. Hypertens. 22 2009 1314 1319
54. P.M. George Viral Toll like receptor activation of pulmonary vascular smooth muscle cells results in endothelin-1 generation; relevance to pathogenesis of pulmonary arterial hypertension Biochem. Biophys. Res. Commun. 426 2012 486 491
55. P. Goossens Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions Cell Metab. 12 2010 142 153
56. M. Ishibashi TLR3 deficiency protects against collagen degradation and medial destruction in murine atherosclerotic plaques Atherosclerosis 229 2013 52 61
57. M. Salagianni Toll-like receptor 7 protects from atherosclerosis by constraining 'inflammatory' macrophage activation Circulation 126 2012 952 962
58. J.C. Karper Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration Arterioscler. Thromb. Vasc. Biol. 32 2012 e72 e80
59. T. Oka Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure Nature 485 2012 251 255
60. I. De Meyer Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques Basic Res. Cardiol. 107 2012 269
61. F. Arslan Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody Circulation 121 2010 80 90
62. F. Arslan Treatment with OPN-305, a humanized anti-Toll-like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs Circ. Cardiovasc. Interv. 5 2012 279 287
63. G.F. Bomfim Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats Clin. Sci. (Lond.) 122 2012 535 543
64. Z. Lu TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice J. Endocrinol. 216 2013 61 71
65. H. von Bernuth Pyogenic bacterial infections in humans with MyD88 deficiency Science 321 2008 691 696
66. Y. Zhang Toll-like receptor -1, -2, and -6 polymorphisms and pulmonary tuberculosis susceptibility: a systematic review and meta-analysis PLoS ONE 8 2013 e63357
67. C.L. Ku Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity J. Exp. Med. 204 2007 2407 2422
68. C. Picard Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency Medicine 89 2010 403 425
69. C. Monaco Toll-like receptor signaling: common pathways that drive cardiovascular disease and rheumatoid arthritis Arthritis Care Res. 63 2011 500 511